-
UPCOMING EVENTS
SMC to attend Japan-UK Virtual Partnering!
2022.12.28
We are pleased to announce that SMC Laboratories will be participating in the Japan-UK Virtual Partnering Online Event from January 23rd (Mon) to February 13th (Mon).
-
NEWS RELEASE
Fibrosis is involved in many diseases and disease-related deaths
2022.12.20
Today's topic is Fibrosis.
-
PUBLICATION
Study on the efficacy of dietary supplements in the STAM™ model published in Cell Death & Disease.
2022.12.13
SMC is proud to announce that J2H biotech (KOR) has published the results of their study using our pre-clinical services with STAM™ model in Cell Death & Disease.
-
PRODUCTS AND SERVICES
Introduction of STAM™ model for pre-clinical studies for liver cancer
2022.12.05
Today, we give you a brief introduction to our proprietary NASH-HCC model (STAM™ model).
-
PUBLICATION
2022.11.30
SMC is proud to announce that GN Corporation Co. Ltd (JPN) has published the results of their study using our STAM™ model in BMJ Open Gastroenterology.
-
PUBLICATION
Drug Efficacy Study in the STAM™ Model Published in Biomedicines.
2022.11.24
SMC is proud to announce that MRM Health (BEL) has published the results of their study using our STAM™ model in Biomedicines.
-
PRODUCTS AND SERVICES
Introducing our new skin disease model: Imiquimod (IMQ)-induced psoriasis model
2022.11.16
We are pleased to announce that we have expanded our preclinical model lineup by including the "Imiquimod (IMQ)-induced dermatitis model" for psoriasis.
-
NEWS RELEASE
Introduction of MAFLD criteria and the disease model
2022.11.09
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept in the study of fatty liver disease.
-
PUBLICATION
2022.11.02
Today, I would like to share with you some wonderful and exciting news! Recently, a client of ours from the National Defense Medical College, Dr. Yasuhiro Takihata, gave a presentation on NASH diagnostics at the 40th Annual Meeting of the Japanese Society of Laser Medicine (JSLSM) and was awarded the Annual Meeting Award for his work.
-
PRODUCTS AND SERVICES
Introduction of our Primary sclerosing cholangitis (PSC) mice model
2022.10.26
Today, I would like to give you a brief introduction into primary sclerosing cholangitis (PSC), as well as our 3,5-Diethoxycarbonyl-1,4-Dihydrocollidine (DDC) mouse model.
-
NEWS RELEASE
The effect of the gut-liver axis dysfunction in liver disease
2022.10.20
Today, I would like to introduce the relationship between Nonalcoholic steatohepatitis (NASH) and the gut.
-
PUBLICATION
Drug Efficacy Study in the STAM™ Model Published in Cells
2022.10.12
SMC is proud to announce that Cellaïon (BEL) has published the results of their study using our STAM™ model in Cells.
